Edgewise Therapeutics Inc (EWTX) concluded trading on Wednesday at a closing price of $15.52, with 16.11 million shares of worth about $250.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.85% during that period and on April 03, 2025 the price saw a loss of about -22.90%. Currently the company’s common shares owned by public are about 94.84M shares, out of which, 67.23M shares are available for trading.
Stock saw a price change of -30.28% in past 5 days and over the past one month there was a price change of -36.65%. Year-to-date (YTD), EWTX shares are showing a performance of -41.87% which decreased to -13.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $14.90 but also hit the highest price of $38.12 during that period. The average intraday trading volume for Edgewise Therapeutics Inc shares is 1.18 million. The stock is currently trading -36.00% below its 20-day simple moving average (SMA20), while that difference is down -39.94% for SMA50 and it goes to -39.05% lower than SMA200.
Edgewise Therapeutics Inc (NASDAQ: EWTX) currently have 94.84M outstanding shares and institutions hold larger chunk of about 78.77% of that.
The stock has a current market capitalization of $1.48B and its 3Y-monthly beta is at 0.33. It has posted earnings per share of -$1.45 in the same period. It has Quick Ratio of 19.93 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EWTX, volatility over the week remained 14.78% while standing at 10.28% over the month.
Stock’s fiscal year EPS is expected to drop by -29.59% while it is estimated to decrease by -9.10% in next year. EPS is likely to grow at an annualized rate of -12.71% for next 5-years, compared to annual growth of -49.00% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on April 02, 2025 offering a Sector perform rating for the stock and assigned a target price of $14 to it. Coverage by Scotiabank stated Edgewise Therapeutics Inc (EWTX) stock as a Sector outperform in their note to investors on March 07, 2025, suggesting a price target of $50 for the stock. On January 22, 2025, Stifel Initiated their recommendations, while on November 22, 2024, Evercore ISI Initiated their ratings for the stock with a price target of $45. Stock get an Overweight rating from Piper Sandler on March 07, 2024.
